Combination GLP-1 and SGLT2 therapy may lower heart risk

Дата публикации: 25-06-2026 13:19:59

PHILADELPHIA — Using a GLP-1 receptor agonist in combination with an SGLT2 inhibitor may provide additive cardiovascular and renal benefits for people with type 2 diabetes, according to a speaker at the Heart in Diabetes CME Conference.Silvio E. Inzucchi, MD, medical director at the Yale Diabetes Center and a Healio | Endocrine Today Editorial Board Member, said there will likely never be a formal trial conducted assessing CV or kidney outcomes for adults receiving a combination SGLT2 inhibitor and GLP-1. However, Inzucchi said, data from observational studies and other trials may provide

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Obesity presents differently for men compared with women	0	5	01-07-2026
2	Prioritize risk reduction for people with diabetes using CGM	5	7	26-06-2026
3	Expect eGFR dips when using blood pressure-lowering medications	0	7	29-06-2026
4	Recent policy changes impact ‘cardiometabolic care cascade’	0	7	30-06-2026
5	FDA advisory committee for peptides stocked with conflicts of interest	0	5	01-07-2026
6	Understanding environment in cardiometabolic risk	0	5	29-06-2026
7	Respiratory failure, CKD-related mortality rose in 1999-2021	0	7	26-06-2026
8	Cuidar las encías puede ayudar a controlar la diabetes tanto como un segundo fármaco	0	7	20-06-2026
9	How a rare kidney disease gained a robust new therapy pipeline	3	7	24-06-2026
10	Минздрав планирует включить приборы для мониторинга здоровья в программу госгарантий	0	0	12-09-2019

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.healio.com.